This year's American Society of Clinical Oncology (ASCO) conference has been a subdued affair for European pharmaceutical ...
The FDA said in a statement: “Since approval, the FDA has received postmarketing safety data on thromboembolic events, including serious and fatal outcomes, in patients treated with Andexxa. Based on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results